Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
—
—
—
Wanbury Limited is a pharmaceutical company which offers active pharmaceutical ingredient in over 70 countries.
Customise key metrics, see detailed forecasts, download stock data and more
A significant proportion of promoter holdings is pledged
In last 3 months, mutual fund holding of the company has almost stayed constant
Wanbury Limited has informed the Exchange regarding a press release dated September 09, 2024, titled "Press Release - Wanbury Limited received a Certificate of Suitability (CEP) forthe launch of its new product, Dextromethorphan (API)". | Download
Wanbury Limited has informed the Exchange regarding a press release dated September 09, 2024, titled "Press Release - Wanbury Limited received a Certificate of Suitability (CEP) forthe launch of its new product, Dextromethorphan (API)". | Download
Final • Div/Share: ₹ 1
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant